Connect with us

Business

Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency – Yahoo Finance

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in a Phase 2 proof-of-concept study, VX-864 achieved…

Published

on

Article feature image
ADVERTISEMENT

– Treatment with VX-864 led to a statistically significant increase from baseline in plasma functional AAT levels as compared to placebo and was generally well tolerated –
– Results provide proof-of-mechanism, although magnitude of treatment effect observed…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Target Deal Days 2021: Best Target sales to shop on Prime Day – NBC News
Article feature image
Coinbase Cofounder Issues Serious Crypto Price Warning As Bitcoin ‘Death Cross’ Fear Spreads – Forbes
Article feature image
After Elon Musk Sparked A Dogecoin Boom, Ethereum Cofounder And Cardano Creator Calls For Doge Price ‘Floor’ Upgrade – Forbes